Dosing initiated for SION-451 combined with SION-2222 and SION-451 combined with SION-109 in healthy volunteers; topline data anticipated in mid-2026 WALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- ...

Caribou Biosciences announces new clinical trials and leadership appointments, highlighting progress in CAR-T therapy for various cancers and lupus. Caribou Biosciences, Inc. announced the initiation ...

WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, a clinical-stage biopharmaceutical company utilizing its proprietary ReSOLVE™ platform to discover and develop differentiated ...

In an interview on the first-in-human phase 1 study of gintemetostat, Saad Z. Usmani, MD, PhD, detailed the initial safety ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Prior to this trial, CS014 had positive outcomes in an ...

Please provide your email address to receive an email when new articles are posted on . One in six participants in phase 2 cancer trials received a therapy that gained FDA approval. The results ...

ASCEND to evaluate CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types, including NSCLC and gastrointestinal and gynecological cancers in first-line and previously treated patient ...

Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell therapies in the confirmatory cohort (N=22) and with ...

Ventus Therapeutics announced the successful completion of the phase 1 clinical trial for VENT-03 with plans to initiate a phase 2 study for people with systemic lupus erythematosus (SLE) in 2025. The ...

A recently launched Phase 1 clinical trial at Mass General Brigham is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem ...